Search filters

Filters

Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 152
  • 17
  • 402
  • 1246
  • 593
  • 29
  • 49
  • 3
  • 1172
  • 1247
  • 6
  • 4
  • 1249

Found 1253 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 16520: A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

All genders
Phase 1
This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation). Patients with driver mutations in EGFR, ALK, …

UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer

All genders
Phase 2
This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer …

A Randomized Double-blind Multicenter Placebo-controlled Study to Evaluate the Efficacy Safety and Tolerability of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants with Treatment-resistant Depression

All genders
Phase 3
this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 mg and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with TRD, as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from …

Aging Brain Cohort Dedicated to Diversity Study TAU PET

All genders
Phase 2
To collect Tau PET imaging in cognitively normal older African American (AA) adults in the ABCD2 study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the mechanisms and distinctions of age-related cognitive decline and that of Alzheimer's disease. Eligible …

Collection of bone marrow aspirate and biopsies for research

All genders
We want to study the effects of immune therapy for cancer on the normal immune system. Some of the cells of the immune system reside in the bone marrow, and can only be obtained by inserting a needle into the bone marrow (typically done through the back of the hip …

UPCC 19520: An Open-Label Multi-Institutional Pilot Study to Assess The Use of Glucarpidase in Adult Patients With Osteosarcoma Receiving High-Dose Methotrexate

All genders
Phase 1
This study is being done to answer the following question: Does scheduled glucarpidase reduce the levels of methotrexate in patients blood and lead to shorter hospitalizations and a reduction in toxicities? Eligible subjects will be those with osteosarcoma.

Matching Perfusion and Metabolic Activity in HFpEF

All genders
Phase 2
This study will test whether Potassium Nitrate (KNO3), with and without Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR), improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF). This study will also test whether the response to supplemental oxygen …

AN EXPLORATORY OPEN-LABEL PROOF-OF-CONCEPT PHASE 2A STUDY OF MAVACAMTEN (MYK-461) IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) AND CHRONIC ELEVATION OF CARDIAC TROPONIN I AND/OR NT-PROBNP

All genders
Phase 2
This is a multicenter, exploratory, open-label study to explore the efficacy and/or pharmacodynamic effect, PK, safety, and tolerability of mavacamten in approximately 35 ambulatory participants with symptomatic HFpEF and elevated cTnI and/or elevated NT-proBNP as defined in inclusion/exclusion criteria. The study will include an up to 7-week screening period (with …

THE ROLE OF T-LYMPHOCYTE BIOLOGY IN CUTANEOUS SQUAMOUS CELL CARCINOMA

All genders
The main goal of this study is to characterize the immunophenotype of those affected with Cutaneous Squamous Cell Carcinoma (cSCC) patients (their skin and blood immunophenotype).

UPCC 14920 A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

All genders
Phase 1
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an IV infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled in the …
361 - 370 of 1253